1Risch NJ. Searching for genetic determinants in the new millennium [J]. Nature,2000,405:847- 856.
2Weinshilboum R. Inheritance and drug response [J]. N Engl J Med,2003,348:529- 537.
3Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy [J]. Cancer Treat Rev,1998,24:331- 344.
4Rosell R,Lord RV,Taron M,et al. DNA repair and cisplatin resistance in non-small-cell lung cancer [J]. Lung Cancer,2002,38:217- 227.
5Lunn RM,Langlois RG,Hsieh LL,et al. XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency [J]. Cancer Res,1999,59:2557- 2561.
6Schiller JH,Harrington D,Belani CP,et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer [J]. N Engl J Med,2002,346:92- 98.
7Zatloukal P,Petruzelka L,Zemanova M,et al. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage Ⅲ b and Ⅳ non-small cell lung cancer: a phase Ⅲ randomized trial [J]. Lung Cancer,2003,41:321- 331.
8Xing D,Qi J,Lin D,et al. Polymorphisms of DNA repair genes XRCC1 and XPD and their associations with risk of esophageal squamous cell carcinoma in a Chinese population [J]. Int J Cancer,2002,100:600- 605.
9Xing D,Tan W,Lin D. Genetic polymorphisms and susceptibility to esophageal cancer among Chinese population(review)[J].Oncol Rep,2003,10:1615- 1623.
10Duell EJ,Millikan RC,Pittman GS,et al. Polymorphisms in the DNA repair gene XRCC1 and breast cancer [J]. Cancer Epidemiol Biomarkers Prev,2001,10:217- 222.
3Zhang Q,Tang X,Zhang Z F,et al.Nicotine induces hypoxia-inducible factor-l alpha expression in human lung cancer cells via nicotinic acetylcholine receptor-mediated signaling pathways[J].Clin Cancer Res,2007,13(16):4686-4694.
4Obermair A,Handisurya A,Kaider A,et al.The relationship of pretreatment serum hemoglobin level to the survival of epithelial ovarian carcinoma patients:a prospective review[J].Cancer,1998,83(4)∶726-731.
